Alkermes reported FY 2025 net income from continuing operations of USD 241.7 million. FY 2025 product sales, net were USD 1.2 billion (+USD 101.1 million), including VIVITROL USD 467.9 million (+USD 10.6 million), ARISTADA/ARISTADA INITIO USD 370.0 million (+USD 23.8 million) and LYBALVI USD 346.7 million (+USD 66.7 million). FY 2025 manufacturing and royalty revenues were USD 291.3 million (down USD 182.8 million), driven primarily by lower long-acting INVEGA product royalties after the U.S. INVEGA SUSTENNA royalty expired in August 2024. FY 2025 R&D expense was USD 324.0 million and SG&A expense was USD 701.5 million; FY 2025 income tax provision was USD 49.8 million with an effective tax rate of 17.1%. Total cash, restricted cash and investments were USD 1.3 billion at December 31, 2025, including USD 731.2 million of restricted cash placed in escrow related to the Avadel acquisition; FY 2025 cash flows provided by operating activities were USD 520.8 million. For business updates, Alkermes entered into a transaction agreement to acquire Avadel in October 2025 (amended November 2025) and incurred approximately USD 10.0 million of acquisition-related costs in Q4 2025; the company completed the acquisition on February 12, 2026, adding LUMRYZ and a narcolepsy-focused commercial organization. Alkermes also said it expects generic versions of VIVITROL to enter the U.S. market in 2027 and disclosed an authorized generic supply agreement with Amneal signed in September 2025 tied to a third-party ANDA product launch.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alkermes plc published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-068925), on February 25, 2026, and is solely responsible for the information contained therein.